|
시장보고서
상품코드
2076882
후성유전학 시장 : 제공별, 제품별, 서비스별, 기술별, 방법별, 용도별, 최종사용자별, 지역별 - 세계 예측(-2031년)Epigenetics Market by Product (Kit, Enzyme), Service (Single-Cell Epigenomics, Multi-omics), Method (DNA Methylation, Histone Modification), Technique (NGS, PCR, MS), Application (Oncology, Immunology, CVD) - Global Forecast to 2031 |
||||||
후성유전학 시장 규모는 2026년 22억 2,000만 달러에서 2031년에는 39억 2,000만 달러에 달할 것으로 예측되며, 예측 기간 동안 CAGR은 12.0%를 기록할 전망입니다.
이 시장은 종양학 연구, 정밀 의학, 신약 개발, 바이오마커 검증 및 중개 연구 분야에서 후성유전학적 분석의 활용 확대에 힘입어, 예측 기간 동안 꾸준한 성장을 이룰 것으로 예상됩니다. 차세대 염기서열 분석, PCR 및 qPCR, 질량 분석, 초음파 처리를 통한 크로마틴 준비, 메틸화 어레이 등의 기술을 통해 DNA 메틸화, 히스톤 변형, 크로마틴 접근성, 비코딩 RNA 및 크로마틴 리모델링을 분석할 수 있습니다. 이러한 도구들은 암 진단, 치료 표적 규명, 질환 분류, 치료 반응 모니터링, 발생 생물학, 면역학, 신경과학, 대사성 질환 연구 등 폭넓은 분야의 응용을 뒷받침하고 있습니다.
| 조사 범위 | |
|---|---|
| 조사 대상 기간 | 2026-2031년 |
| 기준 연도 | 2025년 |
| 예측 기간 | 2026-2031년 |
| 산정 단위 | 금액(10억 달러) |
| 부문 | 제공별, 제품별, 서비스별, 기술별, 방법별, 용도별, 최종사용자별, 지역별 |
| 대상 지역 | 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카 |
액체 생검 기반의 메틸화 바이오마커, 단일 세포 후성유전체학, 멀티오믹스 통합 및 AI를 활용한 데이터 분석의 활용이 확대됨에 따라, 제약, 생명공학, 학술, 임상, CRO 등 각 분야에서 이러한 기술의 도입이 더욱 활발해지고 있습니다. 또한, 표준화된 키트, 고품질 항체, 시퀀싱 시약, 효소, 자동 시료 전처리 솔루션 및 생물정보학 플랫폼에 대한 수요가 증가함에 따라 워크플로우의 재현성과 데이터의 신뢰성이 향상되고 있습니다. 그러나 시퀀싱 및 분석 비용의 높음, 복잡한 데이터 해석, 항체 성능의 편차, 그리고 보다 광범위한 임상 활용을 위한 후성유전학 워크플로우의 표준화 어려움으로 인해 시장 성장은 여전히 과제에 직면해 있습니다.
"DNA 메틸화 부문은 예측 기간 동안 가장 높은 연평균 성장률(CAGR)을 기록할 것으로 예상됩니다."
DNA 메틸화 부문은 암 검출, 바이오마커 발견, 질환 분류 및 치료 반응 모니터링 분야에서 활용이 증가하고 있어, 후성유전학 시장에서 가장 높은 연평균 성장률(CAGR)을 기록할 것으로 전망됩니다. DNA 메틸화 분석법은 프로모터 메틸화, 유전자 침묵, 후성유전적 노화, 종양 프로파일링 및 액체 생검 기반 진단 연구에 널리 활용되고 있습니다. 비스설파이트 시퀀싱, 메틸화 특이적 PCR, 메틸화 어레이 및 NGS(차세대 시퀀싱)에 기반한 메틸화 프로파일링의 활용이 확대됨에 따라, 제약 연구, 임상 검사실 및 중개 연구 분야에서 이에 대한 수요가 증가하고 있습니다.
"차세대 염기서열 분석 분야가 시장에서 가장 큰 점유율을 차지하고 있습니다."
차세대 염기서열 분석(NGS) 부문은 후성유전적 조절에 관한 고처리량 및 유전체 전체에 걸친 인사이트를 도출할 수 있는 능력을 바탕으로, 후성유전학 시장에서 가장 큰 점유율을 차지하고 있습니다. NGS는 DNA 메틸화 프로파일링, ChIP-seq, ATAC-seq, 염색질 접근성 연구 및 단일 세포 후성유전체학 분야에서 널리 활용되고 있습니다. 종양학 연구, 바이오마커 발견, 신약 개발, 그리고 정밀 의학 분야에서의 적극적인 도입이 이 분야의 선도적 위상을 뒷받침하고 있습니다. 보다 상세한 에피유전체 커버리지, 확장 가능한 분석, 그리고 멀티오믹스 워크플로우와의 통합에 대한 수요가 증가함에 따라, NGS 기반 후성유전학 솔루션에 대한 수요는 계속해서 증가하고 있습니다.
"예측 기간 동안 미국은 가장 높은 연평균 성장률(CAGR)을 기록할 것으로 예상됩니다."
미국은 시퀀싱, 분자생물학, 진단, 생물정보학 분야의 기업들이 강력한 입지를 차지하고 있으며, 선진적인 연구 인프라와 연구 및 임상 현장에서의 에피유전체 기술 보급률이 높기 때문에 후성유전학 시장에서 가장 높은 연평균 성장률(CAGR)을 기록할 것으로 예상됩니다. 종양학, 정밀 의학, 신약 개발, 체액 생검 기술 개발 및 바이오마커 검증 분야에서 후성유전학의 활용이 확대되면서 시장 성장을 주도하고 있습니다. 차세대 염기서열 분석, PCR 및 qPCR, 메틸화 어레이, ChIP-seq, ATAC-seq, 단일 세포 후성유전체학 등의 기술은 제약 회사, 생명공학 기업, 학술 기관, CRO, 임상 검사실 등에서 널리 활용되고 있습니다.
Thermo Fisher Scientific Inc.(미국), Merck KGaA(독일), Illumina, Inc.(미국), PacBio(미국), Danaher Corporation(미국), Bio-Rad Laboratories, Inc.(미국), Active Motif, Inc.(미국), New England Biolabs(미국), QIAGEN(네덜란드), Zymo Research Corporation(미국), Revvity(미국), Hologic Diagenode(미국), F. Hoffmann-La Roche Ltd.(스위스), Promega Corporation(미국), EpigenTek Group Inc.(미국), EpiCypher(미국), Fios Genomics(영국), GenomeScan(네덜란드), Creative Biogene(미국), BPS Bioscience, Inc.(미국), Abnova Corporation(대만), Creative Diagnostics(미국), Biomodal(영국), 10x Genomics(미국), Novogene(중국) 등이 후성유전학 관련 제품 및 서비스를 제공하는 주요 기업 중 일부입니다.
조사 범위
본 조사 보고서에서는 후성유전학 시장을 제공 내용(제품 및 서비스), 제품[키트 및 시약{항체, 분리·추출 키트 및 시약, ChIP-시퀀싱 키트 및 시약, 비설파이트 변환 키트 및 시약, 전장 유전체 증폭 키트 및 시약, CUT&RUN/CUT&TAG 키트 및 시약, 5-hmC 및 5-mC 어세이 키트 및 시약, 히스톤, 기타 키트 및 시약}, 효소{DNA 중합효소, DNA 리가아제, Tn5 트랜스포존, 변환 효소[TET 및 APOBEC], 단백질 변형 효소, 기타 효소}, 및 장비·부속품], 서비스(DNA 메틸화 프로파일링 서비스, 염색질 프로파일링 서비스, 크로마틴 접근성 프로파일링 서비스, 단일 세포 후성유전체학 서비스, 멀티오믹스 서비스 및 기타 서비스), 기술(차세대 시퀀싱, PCR 및 qPCR, 질량 분석, 초음파 처리 및 기타 기술), 기법(DNA 메틸화, 히스톤 변형 및 기타 기법), 응용 분야(종양학, 대사성 질환, 면역학, 발생 생물학, 심혈관질환, 집단 스크리닝 및 기타 응용 분야), 최종사용자별 제품 시장(학술·연구 기관, 제약·바이오기술 기업, 병원·진료소 및 수탁 연구 기관), 최종사용자별 서비스 시장(제약·바이오기술 기업, 학술·연구 기관, 병원·진료소 및 수탁 연구 기관), 그리고 지역(북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카)으로 분류되어 있습니다.
본 보고서의 범위에는 후성유전학 시장의 성장에 영향을 미치는 주요 요인(촉진요인, 제약요인, 과제 및 기회 등)에 대한 상세한 정보가 포함되어 있습니다. 주요 업계 참여 기업에 대한 종합적인 분석을 통해 각 기업의 사업 개요, 제품 포트폴리오, 주요 전략, 신제품 출시, 인수합병 및 후성유전학 시장과 관련된 최근 동향에 대한 인사이트를 제공합니다. 또한, 본 보고서에는 후성유전학 업계의 생태계에서 두각을 나타내고 있는 스타트업 기업에 대한 경쟁 분석도 포함되어 있습니다.
본 보고서를 구매할 때의 주요 이점
본 보고서는 시장 전체 및 그 하위 부문의 매출 전망을 제시함으로써, 시장을 선도하는 기업과 신규 진입 기업을 지원합니다. 또한, 이해관계자들이 경쟁 구도를 더 깊이 이해하고, 자사의 비즈니스를 효과적으로 포지셔닝하며, 적절한 시장 진입 전략을 수립하는 데 필요한 인사이트를 얻는 데에도 도움이 됩니다. 본 보고서를 통해 이해관계자들은 시장 동향을 파악하고, 주요 시장 촉진요인, 억제요인, 기회 및 과제에 관한 정보를 얻을 수 있습니다.
본 보고서에서는 다음 사항에 대한 인사이트를 제공합니다:
- 주요 촉진요인(시퀀싱 비용 및 소요 시간의 감소, 집단 선별 검진 프로그램에 대한 관심 증가, 후성유전학 연구 분야의 기술적 진보, 후성유전학 기반 의약품 및 치료법에 대한 수요 증가), 제약요인(독성학 분야에서 에피유전체 데이터의 적용이 제한적임, 데이터 개인정보 보호에 대한 우려 및 보안 문제), 기회(후성유전학의 새로운 응용, 멀티오믹스 통합), 그리고 시장 성장에 영향을 미치는 과제(항체 품질에 대한 우려, 에피제네틱 편집에 수반되는 과제)
- 제품 개발/혁신 : 후성유전학 시장에서 신제품 출시 및 혁신에 대한 상세한 분석
- 시장 개발 : 수익성이 높은 시장에 대한 종합적인 정보 및 각 지역에 걸친 시장 분석
- 시장의 다각화 : 후성유전학 시장의 신제품, 미개척 지역, 최근 동향 및 투자에 관한 종합적인 정보
- 경쟁사 평가 : Thermo Fisher Scientific Inc.(미국), Merck KGaA(독일), Illumina, Inc.(미국), PacBio(미국), Danaher Corporation(미국), Bio-Rad Laboratories, Inc.(미국), Active Motif, Inc.(미국), New England Biolabs(미국), QIAGEN(네덜란드), Zymo Research Corporation(미국), Revvity(미국) 등, 후성유전학 시장의 주요 기업들의 시장 점유율, 성장 전략, 제품 및 서비스에 대한 상세한 평가
자주 묻는 질문
목차
제1장 소개
제2장 주요 요약
제3장 주요 인사이트
제4장 시장 개요
제5장 업계 동향
제6장 기술 진보, AI에 의한 영향, 특허, 혁신, 그리고 향후 응용
제7장 규제 상황과 지속가능성에 대한 대처
제8장 고객 상황과 구매 행동
제9장 후성유전학 시장(제공별)
제10장 후성유전학 시장(제품별)
제11장 후성유전학 시장(서비스별)
제12장 후성유전학 시장(기술별)
제13장 후성유전학 시장(방법별)
제14장 후성유전학 시장(용도별)
제15장 에피제네틱 제품 시장(최종사용자별)
제16장 후성유전학 서비스 시장(최종사용자별)
제17장 후성유전학 시장(지역별)
제18장 경쟁 구도
제19장 기업 개요
제20장 조사 방법
제21장 부록
KSMThe epigenetics market is expected to reach USD 3.92 billion in 2031 from USD 2.22 billion in 2026, at a CAGR of 12.0% during the forecast period. The market is expected to grow steadily during the forecast period, driven by increasing use of epigenetic analysis in oncology research, precision medicine, drug discovery, biomarker validation, and translational studies. Technologies such as next-generation sequencing, PCR & qPCR, mass spectrometry, sonication-based chromatin preparation, and methylation arrays enable the analysis of DNA methylation, histone modifications, chromatin accessibility, non-coding RNAs, and chromatin remodeling. These tools support applications across cancer diagnostics, therapeutic target identification, disease classification, treatment response monitoring, developmental biology, immunology, neuroscience, and metabolic disease research.
| Scope of the Report | |
|---|---|
| Years Considered for the Study | 2026-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD billion) |
| Segments | Offering, Product, Service, Technology, Method, Application, End User (Product), and End User (Service) |
| Regions covered | North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa |
The growing use of liquid biopsy-based methylation biomarkers, single-cell epigenomics, multi-omics integration, and AI-enabled data interpretation is further strengthening adoption across pharmaceutical, biotechnology, academic, clinical, and CRO settings. In addition, demand for standardized kits, high-quality antibodies, sequencing reagents, enzymes, automated sample preparation solutions, and bioinformatics platforms is improving workflow reproducibility and data reliability. However, market growth continues to be challenged by high sequencing and analysis costs, complex data interpretation, variability in antibody performance, and difficulties in standardizing epigenetic workflows for broader clinical use.
"DNA methylation segment is expected to grow at the highest CAGR during the forecast period"
The DNA methylation segment is projected to grow at the highest CAGR in the epigenetics market due to its increasing use in cancer detection, biomarker discovery, disease classification, and treatment response monitoring. DNA methylation assays are widely used to study promoter methylation, gene silencing, epigenetic aging, tumor profiling, and liquid biopsy-based diagnostics. The growing adoption of bisulfite sequencing, methylation-specific PCR, methylation arrays, and NGS-based methylation profiling is strengthening demand across pharmaceutical research, clinical laboratories, and translational studies.
"Next-generation sequencing segment holds the largest share of the market"
The next-generation sequencing segment accounts for the largest share of the epigenetics market, driven by its ability to generate high-throughput, genome-wide insights into epigenetic regulation. NGS is widely used in DNA methylation profiling, ChIP-seq, ATAC-seq, chromatin accessibility studies, and single-cell epigenomics. Its strong adoption across oncology research, biomarker discovery, drug development, and precision medicine supports its leading position. The increasing need for deeper epigenomic coverage, scalable analysis, and integration with multi-omics workflows continues to strengthen demand for NGS-based epigenetics solutions.
"The US is expected to grow at the highest CAGR during the forecast period"
The US is expected to grow at the highest CAGR in the epigenetics market due to its strong presence of sequencing, molecular biology, diagnostics, and bioinformatics companies, advanced research infrastructure, and high adoption of epigenomic technologies across research and clinical settings. Rising use of epigenetics in oncology, precision medicine, drug discovery, liquid biopsy development, and biomarker validation is driving market growth. Technologies such as next-generation sequencing, PCR & qPCR, methylation arrays, ChIP-seq, ATAC-seq, and single-cell epigenomics are widely used across pharmaceutical companies, biotechnology firms, academic institutes, CROs, and clinical laboratories.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side - 70% and Demand Side- 30%
- By Designation: Managers - 45%, CXOs and Directors - 30%, and Executives - 25%
- By Region: North America - 40%, Europe - 25%, Asia Pacific - 25%, Latin America - 5%, the Middle East & Africa - 5%
Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), Active Motif, Inc. (US), New England Biolabs (US), QIAGEN (Netherlands), Zymo Research Corporation (US), Revvity (US), Hologic Diagenode (US), F. Hoffmann-La Roche Ltd. (Switzerland), Promega Corporation (US), EpigenTek Group Inc. (US), EpiCypher (US), Fios Genomics (UK), GenomeScan (Netherlands), Creative Biogene (US), BPS Bioscience, Inc. (US), Abnova Corporation (Taiwan), Creative Diagnostics (US), Biomodal (UK), 10x Genomics (US), and Novogene Co., Ltd. (China) are some of the key companies offering epigenetics products and services.
Research Coverage
This research report categorizes the epigenetics market by offering (products and services), product [kits & reagents {antibodies, isolation/extraction kits & reagents, ChIP-sequencing kits & reagents, bisulfite conversion kits & reagents, whole-genome amplification kits & reagents, CUT&RUN/CUT&TAG kits & reagents, 5-hmC & 5-mC analysis kits & reagents, histones, and other kits & reagents}, enzymes {DNA polymerases, DNA ligases, Tn5 transposase, conversion enzymes [TET & APOBEC], protein-modifying enzymes, and other enzymes}, and instruments & accessories], service (DNA methylation profiling services, chromatin profiling services, chromatin accessibility profiling services, single-cell epigenomics services, multi-omics services, and other services), technology (next-generation sequencing, PCR & qPCR, mass spectrometry, sonication, and other technologies), method (DNA methylation, histone modifications, and other methods), application (oncology, metabolic diseases, immunology, developmental biology, cardiovascular diseases, population screening, and other applications), products market by end user (academic & research institutes, pharmaceutical & biotechnology companies, hospitals & clinics, and contract research organizations), services market by end user (pharmaceutical & biotechnology companies, academic & research institutes, hospitals & clinics, and contract research organizations), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).
The report's scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the epigenetics market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, product portfolio, key strategies, new product launches, acquisitions, and recent developments related to the epigenetics market. This report also includes a competitive analysis of emerging startups in the epigenetics industry ecosystem.
Key Benefits of Buying the Report
The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and offer information on key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
- Analysis of key drivers (declining sequencing costs and time, growing emphasis on population screening programs, technological advancements in epigenetics research, rising demand for epigenetic drugs and epigenetic-based therapeutics), restraints (limited applications of epigenomic data in toxicology, data privacy concerns and security issues), opportunities (emerging applications of epigenetics, integration of multi-omics), and challenges (concerns regarding quality of antibodies, challenges associated with epigenetic editing) influencing the market growth
- Product Development/Innovation: Detailed insights into newly launched products and innovations in the epigenetics market
- Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the epigenetics market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and products & services of leading players like Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), Active Motif, Inc. (US), New England Biolabs (US), QIAGEN (Netherlands), Zymo Research Corporation (US), and Revvity (US), among others, for the epigenetics market
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 MARKET SCOPE
- 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
- 1.3.2 INCLUSIONS & EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.3.4 CURRENCY CONSIDERED
- 1.4 STAKEHOLDERS
- 1.5 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
- 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
- 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
- 2.3 DISRUPTIVE TRENDS IN EPIGENETICS MARKET
- 2.4 HIGH-GROWTH SEGMENTS
- 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
- 3.1 EPIGENETICS MARKET OVERVIEW
- 3.2 NORTH AMERICA: EPIGENETICS MARKET, BY METHOD AND COUNTRY
- 3.3 EPIGENETICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
- 3.4 EPIGENETICS MARKET SHARE, BY OFFERING, 2026 VS. 2031
4 MARKET OVERVIEW
- 4.1 INTRODUCTION
- 4.2 MARKET DYNAMICS
- 4.2.1 DRIVERS
- 4.2.1.1 Declining sequencing costs and time
- 4.2.1.2 Growing emphasis on population-scale screening initiatives
- 4.2.1.3 Technological advancements in epigenetics research
- 4.2.1.4 Rising demand for epigenetic drugs and epigenetic-based therapeutics
- 4.2.2 RESTRAINTS
- 4.2.2.1 Limited applications of epigenomic data in toxicology
- 4.2.2.2 Data privacy concerns and security issues
- 4.2.3 OPPORTUNITIES
- 4.2.3.1 Emerging applications of epigenetics
- 4.2.3.2 Integration of multi-omics
- 4.2.4 CHALLENGES
- 4.2.4.1 Concerns regarding quality of antibodies
- 4.2.4.2 Challenges associated with epigenetic editing
- 4.2.1 DRIVERS
- 4.3 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
- 4.4 STRATEGIC MOVIES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
- 5.1 PORTER'S FIVE FORCES ANALYSIS
- 5.1.1 BARGAINING POWER OF SUPPLIERS
- 5.1.2 BARGAINING POWER OF BUYERS
- 5.1.3 THREAT OF NEW ENTRANTS
- 5.1.4 THREAT OF SUBSTITUTES
- 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.2 MACROECONOMIC OUTLOOK
- 5.2.1 INTRODUCTION
- 5.2.2 GDP TRENDS AND FORECAST
- 5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY
- 5.2.4 TRENDS IN GLOBAL BIOTECH & PHARMA INDUSTRY
- 5.3 VALUE CHAIN ANALYSIS
- 5.4 ECOSYSTEM ANALYSIS
- 5.4.1 ROLE OF PLAYERS IN ECOSYSTEM
- 5.5 PRICING ANALYSIS
- 5.5.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2023-2025
- 5.5.1.1 Average selling price trend, by instrument, 2023-2025
- 5.5.1.2 Average selling price trend, by kits & reagents, 2023-2025
- 5.5.2 AVERAGE SELLING PRICE TREND, BY REGION, 2023-2025
- 5.5.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2023-2025
- 5.6 TRADE ANALYSIS
- 5.6.1 IMPORT SCENARIO (HS CODE 9027.50)
- 5.6.2 EXPORT SCENARIO (HS CODE 9027.50)
- 5.6.3 IMPORT SCENARIO (HS CODE 3822.00)
- 5.6.4 EXPORT SCENARIO (HS CODE 3822.00)
- 5.7 KEY CONFERENCES & EVENTS, 2026-2027
- 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
- 5.9 INVESTMENT & FUNDING SCENARIO
- 5.10 CASE STUDY ANALYSIS
- 5.10.1 CFDNA METHYLOME-FRAGMENTOME PROFILING STRENGTHENS MULTICANCER DETECTION
- 5.10.2 5-BASE NGS WORKFLOW ENABLES INTEGRATED METHYLATION AND VARIANT PROFILING
- 5.10.3 LONG-READ SEQUENCING SCALES NATIVE EPIGENOME ANALYSIS IN AGING RESEARCH
- 5.11 IMPACT OF 2025 US TARIFF ON EPIGENETICS MARKET
- 5.11.1 INTRODUCTION
- 5.11.2 KEY TARIFF RATES
- 5.11.3 PRICE IMPACT ANALYSIS
- 5.11.4 IMPACT ON COUNTRIES/REGIONS
- 5.11.4.1 US
- 5.11.4.2 Europe
- 5.11.4.3 Asia Pacific
- 5.11.5 IMPACT ON END-USE INDUSTRIES
- 5.11.5.1 Pharmaceutical and biotechnology companies
- 5.11.5.2 Contract research organizations
- 5.11.5.3 Academic and research institutes
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
- 6.1 INTRODUCTION
- 6.1.1 KEY TECHNOLOGIES
- 6.1.1.1 DNA methylation conversion technologies
- 6.1.1.2 Chromatin immunoprecipitation/ChIP
- 6.1.1.3 ATAC-based chromatin accessibility profiling
- 6.1.2 COMPLEMENTARY TECHNOLOGIES
- 6.1.2.1 Single-cell partitioning and epigenomic barcoding
- 6.1.2.2 AI/ML-based epigenomic interpretation
- 6.1.3 ADJACENT TECHNOLOGIES
- 6.1.3.1 CRISPR-based epigenome modulation
- 6.1.3.2 Spatial epigenomics
- 6.1.1 KEY TECHNOLOGIES
- 6.2 TECHNOLOGY ROADMAP
- 6.3 PATENT ANALYSIS
- 6.3.1 METHODOLOGY
- 6.3.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE
- 6.3.3 LIST OF KEY PATENTS
- 6.4 FUTURE APPLICATIONS
- 6.5 IMPACT OF AI/GEN AI ON EPIGENETICS MARKET
- 6.5.1 TOP USE CASES AND MARKET POTENTIAL
- 6.5.2 BEST PRACTICES IN AI-ENABLED EPIGENETICS WORKFLOWS
- 6.5.3 CASE STUDIES OF AI IMPLEMENTATION IN EPIGENETICS MARKET
- 6.5.4 INTERCONNECTED ECOSYSTEM AND IMPACT ON MARKET PLAYERS
- 6.5.5 CLIENTS' READINESS TO ADOPT AI-INTEGRATED EPIGENETICS TECHNOLOGIES
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
- 7.1 REGIONAL REGULATIONS AND COMPLIANCE
- 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 7.1.2 INDUSTRY STANDARDS
- 7.1.2.1 North America
- 7.1.2.2 Europe
- 7.1.2.3 Asia Pacific
- 7.1.2.4 Rest of the World
- 7.2 SUSTAINABILITY INITIATIVES
- 7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
- 7.4 CERTIFICATIONS, LABELING, & ECO-STANDARDS
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
- 8.1 DECISION-MAKING PROCESS
- 8.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
- 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 8.2.2 KEY BUYING CRITERIA
- 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
- 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9 EPIGENETICS MARKET, BY OFFERING
- 9.1 INTRODUCTION
- 9.2 PRODUCTS
- 9.2.1 RISING ADOPTION OF WORKFLOW-READY EPIGENETICS PRODUCTS TO PROPEL MARKET
- 9.3 SERVICES
- 9.3.1 RISING OUTSOURCING OF COMPLEX EPIGENOMIC WORKFLOWS TO DRIVE MARKET
10 EPIGENETICS MARKET, BY PRODUCT
- 10.1 INTRODUCTION
- 10.2 KITS & REAGENTS
- 10.2.1 ANTIBODIES
- 10.2.1.1 Growing demand for recombinant antibodies for detection of epigenetic targets to propel market
- 10.2.2 ISOLATION/EXTRACTION KITS & REAGENTS
- 10.2.2.1 Rising need for high-quality, automation-ready sample preparation to propel market
- 10.2.3 CHIP-SEQUENCING KITS & REAGENTS
- 10.2.3.1 Versatile applications of chromatin immunoprecipitation pertaining to epigenetic regulatory systems to boost market
- 10.2.4 BISULFITE CONVERSION KITS & REAGENTS
- 10.2.4.1 Effective outcomes associated with bisulfite conversion to sustain growth
- 10.2.5 WHOLE-GENOME AMPLIFICATION KITS & REAGENTS
- 10.2.5.1 Rising use of low-input and single-cell epigenomic workflows to stimulate growth
- 10.2.6 CUT&RUN/CUT&TAG KITS & REAGENTS
- 10.2.6.1 Rising adoption of low-input chromatin profiling workflows to stimulate growth
- 10.2.7 5-HMC & 5-MC ANALYSIS KITS & REAGENTS
- 10.2.7.1 Introduction of unique kits for 5-mC and 5-hmC analysis to support growth
- 10.2.8 HISTONES
- 10.2.8.1 Rising importance of chromatin-associated proteins and histones in epigenetic research to propel growth
- 10.2.9 OTHER KITS & REAGENTS
- 10.2.1 ANTIBODIES
- 10.3 ENZYMES
- 10.3.1 DNA POLYMERASES
- 10.3.1.1 Rising need for uracil-tolerant, low-bias DNA amplification to facilitate growth
- 10.3.2 DNA LIGASES
- 10.3.2.1 Rising need for efficient adapter ligation in low-input epigenomic library preparation to spur growth
- 10.3.3 TN5 TRANSPOSASE
- 10.3.3.1 Rising adoption of tagmentation-based chromatin profiling to facilitate growth
- 10.3.4 CONVERSION ENZYMES
- 10.3.4.1 Rising shift toward enzymatic DNA conversion for low-damage methylome profiling to spur growth
- 10.3.5 PROTEIN-MODIFYING ENZYMES
- 10.3.5.1 Rising focus on histone post-translational modification analysis to spur growth
- 10.3.6 OTHER ENZYMES
- 10.3.1 DNA POLYMERASES
- 10.4 INSTRUMENTS & ACCESSORIES
- 10.4.1 RISING ADOPTION OF HIGH-THROUGHPUT, AUTOMATED, AND LONG-READ EPIGENOMIC PLATFORMS TO EXPEDITE GROWTH
11 EPIGENETICS MARKET, BY SERVICE
- 11.1 INTRODUCTION
- 11.2 DNA METHYLATION PROFILING SERVICES
- 11.2.1 OUTSOURCING OF COMPLEX METHYLATION WORKFLOWS AND ONCOLOGY BIOMARKER RESEARCH TO DRIVE MARKET
- 11.3 CHROMATIN PROFILING SERVICES
- 11.3.1 RISING OUTSOURCING OF LOW-INPUT AND MULTI-OMIC CHROMATIN MAPPING WORKFLOWS TO DRIVE MARKET
- 11.4 CHROMATIN ACCESSIBILITY PROFILING SERVICES
- 11.4.1 RISING USE OF SINGLE-CELL EPIGENOMIC PROFILING IN EMBRYO AND LINEAGE-DEVELOPMENT RESEARCH TO PROPEL MARKET
- 11.5 SINGLE-CELL EPIGENOMICS SERVICES
- 11.5.1 RISING NEED FOR CELL-LEVEL REGULATORY INSIGHTS TO AID GROWTH
- 11.6 MULTI-OMICS SERVICES
- 11.6.1 RISING DEMAND FOR INTEGRATED EPIGENOMIC, GENOMIC, AND TRANSCRIPTOMIC INTERPRETATION TO SUPPORT GROWTH
- 11.7 OTHER SERVICES
12 EPIGENETICS MARKET, BY TECHNOLOGY
- 12.1 INTRODUCTION
- 12.2 NEXT-GENERATION SEQUENCING
- 12.2.1 INCREASING LAUNCHES OF NGS PLATFORMS TO DRIVE GROWTH
- 12.3 PCR & QPCR
- 12.3.1 RISING NUMBER OF PCR-BASED EPIGENETICS SERVICE PROVIDERS TO DRIVE MARKET
- 12.4 MASS SPECTROMETRY
- 12.4.1 GROWING DEMAND FOR MASS SPECTROMETRY IN COMPREHENSIVE STUDIES ON HISTONE EPIGENETICS TO BOOST MARKET
- 12.5 SONICATION
- 12.5.1 RISING USE OF SONICATION IN SCIENTIFIC AND INDUSTRIAL SETTINGS TO DRIVE MARKET
- 12.6 OTHER TECHNOLOGIES
13 EPIGENETICS MARKET, BY METHOD
- 13.1 INTRODUCTION
- 13.2 DNA METHYLATION
- 13.2.1 RISING USE OF METHYLATION-BASED BIOMARKERS IN ONCOLOGY, LIQUID BIOPSY, AND PRECISION MEDICINE TO SPUR GROWTH
- 13.3 HISTONE MODIFICATION
- 13.3.1 EXPANDING USE OF HISTONE MODIFICATION PROFILING IN CHROMATIN BIOLOGY, DRUG DISCOVERY, AND MULTI-OMICS RESEARCH TO DRIVE MARKET
- 13.4 OTHER METHODS
14 EPIGENETICS MARKET, BY APPLICATION
- 14.1 INTRODUCTION
- 14.2 ONCOLOGY
- 14.2.1 RISING USE OF EPIGENETIC BIOMARKERS AND CHROMATIN-REGULATING DRUG TARGETS TO BOOST MARKET
- 14.3 METABOLIC DISEASES
- 14.3.1 INCREASING USE OF DNA METHYLATION BIOMARKERS TO ADVANCE METABOLIC DISEASE RISK PREDICTION AND THERAPEUTIC RESEARCH
- 14.4 IMMUNOLOGY
- 14.4.1 RISING USE OF EPIGENETIC IMMUNE PROFILING TO DRIVE MARKET
- 14.5 DEVELOPMENTAL BIOLOGY
- 14.5.1 INCREASED USE OF SINGLE-CELL EPIGENOMIC PROFILING IN EMBRYO AND LINEAGE-DEVELOPMENT RESEARCH TO PROPEL MARKET
- 14.6 CARDIOVASCULAR DISEASES
- 14.6.1 RISING USE OF DNA METHYLATION BIOMARKERS FOR CARDIOVASCULAR RISK PREDICTION AND THERAPEUTIC TARGET DISCOVERY TO AID GROWTH
- 14.7 POPULATION SCREENING
- 14.7.1 INCREASING USE OF DNA METHYLATION BIOMARKERS FOR EXPOSURE-LINKED POPULATION RISK ASSESSMENT TO AID GROWTH
- 14.8 OTHER APPLICATIONS
15 EPIGENETIC PRODUCTS MARKET, BY END USER
- 15.1 INTRODUCTION
- 15.2 ACADEMIC & RESEARCH INSTITUTES
- 15.2.1 INCREASED IN-HOUSE ADOPTION OF ADVANCED EPIGENOMICS PRODUCTS ACROSS ACADEMIC DISCOVERY RESEARCH TO FAVOR GROWTH
- 15.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 15.3.1 RISING USE OF EPIGENETICS PRODUCTS IN DRUG DISCOVERY TO PROPEL MARKET
- 15.4 HOSPITALS & CLINICS
- 15.4.1 RISING INTEGRATION OF METHYLATION-BASED MOLECULAR PROFILING IN HOSPITAL ONCOLOGY WORKFLOWS TO PROPEL MARKET
- 15.5 CONTRACT RESEARCH ORGANIZATIONS
- 15.5.1 INCREASING DEMAND FOR STANDARDIZED AND SCALABLE EPIGENOMIC WORKFLOWS TO DRIVE MARKET
16 EPIGENETICS SERVICES MARKET, BY END USER
- 16.1 INTRODUCTION
- 16.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 16.2.1 RISING USE OF OUTSOURCED EPIGENETIC BIOMARKER AND TARGET-VALIDATION SERVICES TO ACCELERATE DRUG DEVELOPMENT DECISIONS
- 16.3 ACADEMIC & RESEARCH INSTITUTES
- 16.3.1 INCREASING VOLUME OF HIGH-THROUGHPUT EPIGENOMIC DATA TO AUGMENT GROWTH
- 16.4 HOSPITALS & CLINICS
- 16.4.1 RISING USE OF OUTSOURCED METHYLATION PROFILING AND CLASSIFIER-BASED INTERPRETATION TO AID GROWTH
17 EPIGENETICS MARKET, BY REGION
- 17.1 INTRODUCTION
- 17.2 NORTH AMERICA
- 17.2.1 US
- 17.2.1.1 Strong pharmaceutical R&D intensity and advanced genomics infrastructure to drive market
- 17.2.2 CANADA
- 17.2.2.1 Presence of advanced clinical genomics infrastructure to support market growth
- 17.2.1 US
- 17.3 EUROPE
- 17.3.1 GERMANY
- 17.3.1.1 Established life sciences supply ecosystem to drive market
- 17.3.2 UK
- 17.3.2.1 Growing emphasis on precision medicine to propel market
- 17.3.3 FRANCE
- 17.3.3.1 Strong oncology research ecosystem to support market growth
- 17.3.4 ITALY
- 17.3.4.1 High incidence of cancer to drive market
- 17.3.5 SPAIN
- 17.3.5.1 Well-established network of research centers and universities to propel market
- 17.3.6 REST OF EUROPE
- 17.3.1 GERMANY
- 17.4 ASIA PACIFIC
- 17.4.1 CHINA
- 17.4.1.1 Advanced methylation detection and sequencing service capacity to accelerate growth
- 17.4.2 JAPAN
- 17.4.2.1 Increasing collaborations between research & academic organizations to favor growth
- 17.4.3 INDIA
- 17.4.3.1 Expanding genomics infrastructure to drive market
- 17.4.4 AUSTRALIA
- 17.4.4.1 Strong genomics infrastructure to propel market
- 17.4.5 SOUTH KOREA
- 17.4.5.1 Methylation profiling and AI-enabled epigenomic analysis to foster growth
- 17.4.6 REST OF ASIA PACIFIC
- 17.4.1 CHINA
- 17.5 LATIN AMERICA
- 17.5.1 BRAZIL
- 17.5.1.1 Rising prevalence of chronic diseases to drive market
- 17.5.2 MEXICO
- 17.5.2.1 Growing adoption of cutting-edge technologies to drive market
- 17.5.3 REST OF LATIN AMERICA
- 17.5.1 BRAZIL
- 17.6 MIDDLE EAST
- 17.6.1 GCC COUNTRIES
- 17.6.1.1 Saudi Arabia
- 17.6.1.1.1 Growing healthcare expenditure to propel market
- 17.6.1.2 UAE
- 17.6.1.2.1 National genomics programs and methylation-enabled sequencing to spur growth
- 17.6.1.3 Rest of GCC countries
- 17.6.1.1 Saudi Arabia
- 17.6.2 REST OF MIDDLE EAST
- 17.6.1 GCC COUNTRIES
- 17.7 AFRICA
- 17.7.1 POPULATION-SPECIFIC BIOMARKER DISCOVERY AND DISEASE-FOCUSED METHYLATION RESEARCH TO AUGMENT GROWTH
18 COMPETITIVE LANDSCAPE
- 18.1 INTRODUCTION
- 18.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, JANUARY 2023-MAY 2026
- 18.3 REVENUE ANALYSIS
- 18.4 MARKET SHARE ANALYSIS, 2025
- 18.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
- 18.5.1 STARS
- 18.5.2 EMERGING LEADERS
- 18.5.3 PERVASIVE PLAYERS
- 18.5.4 PARTICIPANTS
- 18.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
- 18.5.5.1 Company footprint
- 18.5.5.2 Region footprint
- 18.5.5.3 Product footprint
- 18.5.5.4 Service footprint
- 18.5.5.5 Method footprint
- 18.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
- 18.6.1 PROGRESSIVE COMPANIES
- 18.6.2 RESPONSIVE COMPANIES
- 18.6.3 DYNAMIC COMPANIES
- 18.6.4 STARTING BLOCKS
- 18.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
- 18.6.5.1 Detailed list of key startups/SMEs
- 18.6.5.2 Competitive benchmarking of key startups/SMEs
- 18.7 COMPANY VALUATION AND FINANCIAL METRICS
- 18.7.1 COMPANY VALUATION
- 18.7.2 FINANCIAL METRICS
- 18.8 BRAND COMPARISON
- 18.9 COMPETITIVE SCENARIO
- 18.9.1 PRODUCT/SERVICE LAUNCHES
- 18.9.2 DEALS
19 COMPANY PROFILES
- 19.1 KEY PLAYERS
- 19.1.1 THERMO FISHER SCIENTIFIC INC.
- 19.1.1.1 Business overview
- 19.1.1.2 Products/services offered
- 19.1.1.3 Recent developments
- 19.1.1.3.1 Product launches
- 19.1.1.3.2 Deals
- 19.1.1.4 MnM view
- 19.1.1.4.1 Key strengths
- 19.1.1.4.2 Strategic choices
- 19.1.1.4.3 Weaknesses and competitive threats
- 19.1.2 ILLUMINA, INC.
- 19.1.2.1 Business overview
- 19.1.2.2 Products/Services offered
- 19.1.2.3 Recent developments
- 19.1.2.3.1 Product launches
- 19.1.2.3.2 Deals
- 19.1.2.4 MnM view
- 19.1.2.4.1 Key strengths
- 19.1.2.4.2 Strategic choices
- 19.1.2.4.3 Weaknesses and competitive threats
- 19.1.3 MERCK KGAA
- 19.1.3.1 Business overview
- 19.1.3.2 Products/Services offered
- 19.1.3.3 MnM view
- 19.1.3.3.1 Key strengths
- 19.1.3.3.2 Strategic choices
- 19.1.3.3.3 Weaknesses and competitive threats
- 19.1.4 DANAHER CORPORATION
- 19.1.4.1 Business overview
- 19.1.4.2 Products/Services offered
- 19.1.4.3 Recent developments
- 19.1.4.3.1 Deals
- 19.1.4.4 MnM view
- 19.1.4.4.1 Key strengths
- 19.1.4.4.2 Strategic choices
- 19.1.4.4.3 Weaknesses and competitive threats
- 19.1.5 BIO-RAD LABORATORIES, INC.
- 19.1.5.1 Business overview
- 19.1.5.2 Products/Services offered
- 19.1.5.3 MnM view
- 19.1.5.3.1 Key strengths
- 19.1.5.3.2 Strategic choices
- 19.1.5.3.3 Weaknesses and competitive threats
- 19.1.6 REVVITY
- 19.1.6.1 Business overview
- 19.1.6.2 Products/Services offered
- 19.1.7 PACBIO
- 19.1.7.1 Business overview
- 19.1.7.2 Products/Services offered
- 19.1.7.3 Recent developments
- 19.1.7.3.1 Product launches
- 19.1.7.3.2 Deals
- 19.1.8 ACTIVE MOTIF, INC.
- 19.1.8.1 Business overview
- 19.1.8.2 Products/Services offered
- 19.1.8.3 Recent developments
- 19.1.8.3.1 Deals
- 19.1.9 NEW ENGLAND BIOLABS
- 19.1.9.1 Business overview
- 19.1.9.2 Products/Services offered
- 19.1.9.3 Recent developments
- 19.1.9.3.1 Product launches
- 19.1.9.3.2 Deals
- 19.1.10 QIAGEN
- 19.1.10.1 Business overview
- 19.1.10.2 Products/services offered
- 19.1.10.3 Recent developments
- 19.1.10.3.1 Product launches
- 19.1.11 ZYMO RESEARCH CORPORATION
- 19.1.11.1 Business overview
- 19.1.11.2 Products/Services offered
- 19.1.11.3 Recent developments
- 19.1.11.3.1 Product launches
- 19.1.11.3.2 Deals
- 19.1.12 HOLOGIC DIAGENODE
- 19.1.12.1 Business overview
- 19.1.12.2 Products/services offered
- 19.1.13 F. HOFFMANN-LA ROCHE LTD.
- 19.1.13.1 Business overview
- 19.1.13.2 Products/services offered
- 19.1.14 PROMEGA CORPORATION
- 19.1.14.1 Business overview
- 19.1.14.2 Products/services offered
- 19.1.15 EPIGENTEK GROUP INC.
- 19.1.15.1 Business overview
- 19.1.15.2 Products/Services offered
- 19.1.15.3 Recent developments
- 19.1.15.3.1 Product launches
- 19.1.1 THERMO FISHER SCIENTIFIC INC.
- 19.2 OTHER PLAYERS
- 19.2.1 EPICYPHER
- 19.2.2 FIOS GENOMICS
- 19.2.3 GENOMESCAN
- 19.2.4 CREATIVE BIOGENE
- 19.2.5 BPS BIOSCIENCE, INC.
- 19.2.6 ABNOVA CORPORATION
- 19.2.7 CREATIVE DIAGNOSTICS
- 19.2.8 BIOMODAL
- 19.2.9 10X GENOMICS
- 19.2.10 NOVOGENE CO., LTD.
20 RESEARCH METHODOLOGY
- 20.1 RESEARCH DATA
- 20.1.1 SECONDARY DATA
- 20.1.1.1 Key data from secondary sources
- 20.1.2 PRIMARY DATA
- 20.1.2.1 Key data from primary sources
- 20.1.2.2 Key primary participants
- 20.1.2.3 Breakdown of primary interviews
- 20.1.2.4 Key industry insights
- 20.1.1 SECONDARY DATA
- 20.2 MARKET SIZE ESTIMATION
- 20.2.1 GLOBAL EPIGENETICS MARKET ESTIMATION, 2025
- 20.2.2 SEGMENTAL MARKET SIZE ESTIMATION
- 20.3 MARKET GROWTH RATE PROJECTIONS
- 20.4 DATA TRIANGULATION
- 20.5 FACTOR ANALYSIS
- 20.6 RESEARCH ASSUMPTIONS
- 20.7 RESEARCH LIMITATIONS AND RISK ASSESSMENT
21 APPENDIX
- 21.1 DISCUSSION GUIDE
- 21.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 21.3 CUSTOMIZATION OPTIONS
- 21.4 RELATED REPORTS
- 21.5 AUTHOR DETAILS
